首页> 外国专利> regulatory T cells and their use in immunotherapy and suppression of autoimmune responses

regulatory T cells and their use in immunotherapy and suppression of autoimmune responses

机译:调节性T细胞及其在免疫治疗和自身免疫应答抑制中的用途

摘要

A method for producing therapeutic CD4 + CD25 + CD62 + CD27 + regulatory T cells (Treg cells), wherein said method comprises: isolating a population of human CD4 + CD25 + suppressor T cells from a sample of CD4 + T cells using column purification that uses CD25 microspheres, where double column purification comprises purification in a first and a second column; and expanding in culture the CD4 + CD25 + Treg cells ex vivo with microspheres coated with antibodies to CD3 and CD28, and expanding in culture said isolated population of human CD4 + CD25 + Treg cells in the presence of IL-2, irradiated CD4 + feeder cell or the medium conditioning of irradiated CD4 + feeder cells, thus producing expanded cells in culture, wherein said expanded Treg cells in culture are CD62L + / CD27 + and are capable of inhibiting proliferation of CD4 + CD25-responsive T cells in a Mixed Lymphocyte Reaction assay ( MLR) for more than 90%.
机译:一种产生治疗性CD4 + CD25 + CD62 + CD27 +调节性T细胞(Treg细胞)的方法,其中所述方法包括:使用柱纯化法从CD4 + T细胞样品中分离出人类CD4 + CD25 +抑制性T细胞群体使用CD25微球,其中双柱纯化包括在第一和第二柱中纯化;并用涂有针对CD3和CD28的抗体的微球离体培养CD4 + CD25 + Treg细胞,并在存在IL-2,照射的CD4 +饲养细胞的情况下,培养所述分离的人类CD4 + CD25 + Treg细胞群体。细胞或经辐照的CD4 +饲养细胞的培养基,从而在培养中产生扩增的细胞,其中所述培养的扩增的Treg细胞为CD62L + / CD27 +并能够抑制混合淋巴细胞中CD4 + CD25应答性T细胞的增殖反应测定(MLR)超过90%。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号